A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.
In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.
Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.
An artificial intelligence–based optical coherence tomography pathway met noninferiority criteria for false-positive diabetic macular edema referrals and was associated with fewer referral decisions in a randomized clinical trial.